Blog
About

52
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references 5

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A serological assay to detect SARS-CoV-2 seroconversion in humans

          SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies. Here we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using recombinant antigens derived from the spike protein of SARS-CoV-2. Using negative control samples representing pre-COVID 19 background immunity in the general adult population as well as samples from COVID19 patients, we demonstrate that these assays are sensitive and specific, allowing for screening and identification of COVID19 seroconverters using human plasma/serum as early as two days post COVID19 symptoms onset. Importantly, these assays do not require handling of infectious virus, can be adjusted to detect different antibody types and are amendable to scaling. Such serological assays are of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic. Sensitive and specific identification of coronavirus SARS-Cov-2 antibody titers may, in the future, also support screening of health care workers to identify those who are already immune and can be deployed to care for infected patients minimizing the risk of viral spread to colleagues and other patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase

             D. Xu,  Z. Zhang,  L. Jin (2005)
            In order to further the present knowledge of the emerging severe acute respiratory syndrome-associated coronavirus (SARS-CoV), 486 different specimens from 54 patients with a clinical diagnosis of SARS were investigated for the presence of viral RNA, and 314 plasma specimens of 73 patients were examined for IgM and IgG antibodies specific against SARS-CoV using an indirect ELISA. Viral RNA was detectable in 28 of the 54 patients tested. Cumulative data showed that 67 of the 73 SARS patients demonstrated seroconversion by week 5 of illness. In contrast, only 1 of 278 healthy subjects enrolled in the study was found to be positive for the IgG antibody. Coexistence of viral RNA in plasma and specific antibodies was simultaneously observed over three consecutive weeks in two critical cases. In three convalescent patients in particular, cultivable SARS-CoV was detected in stool or urine specimens for longer than 4 weeks (29–36 days). These findings suggest that SARS-CoV may remain viable in the excretions of convalescent patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SARS-CoV-2 shedding and infectivity

              Fei Zhou and colleagues 1 estimated mean duration of viral shedding by assessing the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA in patient samples. Assessing potential infectivity is a labour-intensive process, but the presence of nucleic acid alone cannot be used to define viral shedding or infection potential, as the authors state is possible within their methods. For many viral diseases (SARS-CoV, Middle East respiratory syndrome coronavirus, influenza virus, Ebola virus, and Zika virus) it is well known that viral RNA can be detected long after the disappearance of infectious virus.2, 3, 4, 5, 6, 7 With measles virus, viral RNA can still be detected 6–8 weeks after the clearance of infectious virus. 8 The immune system can neutralise viruses by lysing their envelope or aggregating virus particles; these processes prevent subsequent infection but do not eliminate nucleic acid, which degrades slowly over time. We were surprised to note the absence of viral load data in this study. 1 Although the use of sensitive PCR methods offers value from a diagnostic viewpoint, caution is required when applying such data to assess the duration of viral shedding and infection potential because PCR does not distinguish between infectious virus and non-infectious nucleic acid. The timely publication of insightful data is paramount in responding to outbreaks of novel pathogens. However, the findings in this study should not be used to conclude prolonged viral shedding or provide rationale to amend isolation policies, as concluded by the authors; infectivity data are required to demonstrate these specific aspects.
                Bookmark

                Author and article information

                Journal
                Nature Medicine
                Nat Med
                Springer Science and Business Media LLC
                1078-8956
                1546-170X
                June 18 2020
                Article
                10.1038/s41591-020-0965-6
                © 2020

                Free to read

                http://www.springer.com/tdm

                http://www.springer.com/tdm

                Comments

                Comment on this article